Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location - Trial NCT06337591
Access comprehensive clinical trial information for NCT06337591 through Pure Global AI's free database. This phase not specified trial is sponsored by Istituto Nazionale di Ricovero e Cura per Anziani and is currently Completed. The study focuses on Bladder Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Istituto Nazionale di Ricovero e Cura per Anziani
Timeline & Enrollment
N/A
Oct 15, 2022
Mar 10, 2024
Primary Outcome
Sensitivity of Vescical Imaging-Reporting and Data System (VI-RADS) in predicting muscle-invasive bladder cancer after transurethral resection
Summary
VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study
 was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System
 (VI-RADS) for the assessment of muscle invasion (MI) status in comparison with transurethral
 resection of bladder cancer (TURB) and to evaluate the diagnostic accuracy of the score
 according to the specific tumour location.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06337591
Non-Device Trial